AU633561B2 - Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins - Google Patents

Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins

Info

Publication number
AU633561B2
AU633561B2 AU54347/90A AU5434790A AU633561B2 AU 633561 B2 AU633561 B2 AU 633561B2 AU 54347/90 A AU54347/90 A AU 54347/90A AU 5434790 A AU5434790 A AU 5434790A AU 633561 B2 AU633561 B2 AU 633561B2
Authority
AU
Australia
Prior art keywords
tumor
mucin
antigen
human
adenocarcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU54347/90A
Other languages
English (en)
Other versions
AU5434790A (en
Inventor
Peter Y. S. Fung
B. Michael Longenecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU5434790A publication Critical patent/AU5434790A/en
Application granted granted Critical
Publication of AU633561B2 publication Critical patent/AU633561B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU54347/90A 1989-04-05 1990-04-05 Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins Ceased AU633561B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33321989A 1989-04-05 1989-04-05
US333219 1989-04-05

Publications (2)

Publication Number Publication Date
AU5434790A AU5434790A (en) 1990-11-05
AU633561B2 true AU633561B2 (en) 1993-02-04

Family

ID=23301851

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54347/90A Ceased AU633561B2 (en) 1989-04-05 1990-04-05 Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins

Country Status (5)

Country Link
EP (1) EP0466813A4 (ja)
JP (1) JP2984366B2 (ja)
AU (1) AU633561B2 (ja)
CA (1) CA2013966C (ja)
WO (1) WO1990011764A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585512B1 (en) 1990-05-08 2009-09-08 Thomas Jefferson University Composition and method of using tumor cells
NL9300846A (nl) * 1993-05-14 1994-12-01 Friesland Frico Domo Coop Werkwijze voor het screenen van voedingsprodukten op voedingsallergeniteit.
JPH11507633A (ja) * 1995-06-07 1999-07-06 トーマス・ジェファーソン・ユニバーシティ ハプテン修飾された腫瘍細胞抽出物及び癌を治療又はスクリーニングするための方法
ES2485316T3 (es) 2005-09-01 2014-08-13 Celgene Corporation Usos inmunológicos de compuestos inmunomoduladores para vacunas y terapia anti-enfermedades infecciosas
CN115920035A (zh) * 2022-12-28 2023-04-07 广州誉衡生物科技有限公司 一种药物制剂及其在治疗肝癌中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687761A (en) * 1985-05-09 1987-08-18 Yaguang Liu Pharmaceutical composition for increasing immunity and decreasing side effects of anticancer chemotherapy
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
CA1335883C (en) * 1986-07-08 1995-06-13 Bryan Michael Longenecker Enhancement of the cellular immune response
US4971795A (en) * 1986-07-08 1990-11-20 Biomira, Inc. Enhancement of the cellular immune response using carbohydrate primed DTH effector cells expressing the CD5+/CD8- phenotype

Also Published As

Publication number Publication date
WO1990011764A1 (en) 1990-10-18
JP2984366B2 (ja) 1999-11-29
CA2013966C (en) 2000-03-07
CA2013966A1 (en) 1990-10-05
AU5434790A (en) 1990-11-05
EP0466813A4 (en) 1992-07-15
JPH07500565A (ja) 1995-01-19
EP0466813A1 (en) 1992-01-22

Similar Documents

Publication Publication Date Title
Fung et al. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate
EP1940461B1 (en) Concurrent chemotherapy and immunotherapy
Davis et al. Liposomes as adjuvants with immunopurified tetanus toxoid: influence of liposomal characteristics.
Fung et al. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA)
O'Boyle et al. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn
TWI611810B (zh) 具有較高碳水化合物抗原密度之疫苗及其醫藥組成合物
Weiss MER and other mycobacterial fractions in the immunotherapy of cancer
AU1755297A (en) Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
KR100392582B1 (ko) 면역치료제및이의용도
AU745555B2 (en) Fucosyl GM1-KLH conjugate vaccine against small cell lung cancer
US5500215A (en) Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
Motomura et al. HLA-A2 and-A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice
US20020068071A1 (en) Enhancement of the cellular immune response
AU633561B2 (en) Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins
Ravindranath et al. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside
US5792455A (en) Anti-idiotypic antibody vaccines
Rogers et al. Augmentation of in vivo cytotoxic T lymphocyte activity and reduction of tumor growth by large multivalent immunogen.
AU7435887A (en) Vaccine for stimulating or enhancing production of antibodies directed against gm2
US5208022A (en) Non-malignant cells coupled to adjuvants and their use in a method to induce anti-tumor immunity
James et al. Antitumor antibodies and immunoglobulin class and subclass levels in Corynebacterium parvum-treated mice
JP2001508764A (ja) 免疫原性ｔｌｐ組成物
Hearing et al. Suppression of established pulmonary metastases by murine melanoma‐specific monoclonal antibodies
JP2003524583A (ja) 黒色腫患者における肺転移に対して抗腫瘍応答を誘導する方法
Ben-Hur et al. Soluble low-molecular-mass tumor-associated proteins promote the suppression of mammary tumors by cyclophosphamide
RAVINDRANATH DONALD L. MORTON AND